Abiopharma

🔍 Nolan Donald A (Executive)

Company: APOGEE ENTERPRISES, INC. (APOG)

Report Date: 2026-03-31

Detailed Transactions and Holdings:

• Acquired 85 shares of Phantom Stock Units (Derivative)
  Date: 2026-03-31 | Code: A | equity_swap_involved: 0 | shares_owned_after: 10,613.00 | transaction_form_type: 4 | Footnotes: F1, F2, F3, F3
• Acquired 580 shares of Deferred Restricted Stock Units (Derivative)
  Date: 2026-03-31 | Code: A | equity_swap_involved: 0 | shares_owned_after: 72,845.00 | transaction_form_type: 4 | Footnotes: F1, F4, F5, F5

Footnotes:

• F1: Settled 1-for-1.
• F2: Additional phantom stock units acquired pursuant to a dividend equivalent reinvestment feature of the Deferred Compensation Plan for Non-Employee Directors.
• F3: The phantom stock units were allocated under the Deferred Compensation Plan for Non-Employee Directors. The phantom stock units will be settled in shares of common stock following the director's termination from the Board in accordance with the election of the reporting person, or following the occurrence of other events specified in the Plan.
• F4: Additional deferred restricted stock units acquired pursuant to a dividend equivalent reinvestment feature of the 2009 Non-Employee Director Stock Incentive Plan, the 2019 Non-Employee Director Stock Plan and the 2019 Stock Incentive Plan.
• F5: The deferred restricted stock units were allocated under the 2009 Non-Employee Director Stock Incentive Plan, the 2019 Non-Employee Director Stock Plan and the 2019 Stock Incentive Plan. The deferred restricted stock units will be settled in shares of common stock following the director's termination from the Board in accordance with the election of the reporting person, or following the occurrence of other events specified in the Plan.